ARTICLE | Clinical News
SmithKline halts lotrafiban trial
December 12, 2000 8:00 AM UTC
SmithKline (SBH; LSE:SB) discontinued development of lotrafiban, which was in Phase III testing to prevent recurrent strokes and heart attacks, based on the recommendation of an independent data and s...